Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma

The prognosis of patients with unresectable or metastatic urothelial carcinoma (UC) is poor. Platinum-based chemotherapy has been the standard first-line treatment in these patients for the past decade; however, the 5-year overall survival (OS) rate is only 13–22%. Recent advances in cancer immunolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Inokuchi, Junichi, Eto, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526676/
https://www.ncbi.nlm.nih.gov/pubmed/31191013
http://dx.doi.org/10.2147/CMAR.S167708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526676/
https://www.ncbi.nlm.nih.gov/pubmed/31191013
http://dx.doi.org/10.2147/CMAR.S167708

Ejemplares similares